Celgene strengthens its cancer portfolio by acquiring Impact Biomedicines. After stopping the Crohn's disease treatment trials and cutting down the 2020 outlook recently, this deal is a positive news for Celgene. But Sanofi had sold the rights of fedrantinib to Impact in 2016 when the drug was having some glitches at that time. A new filing for fedrantinib is planned in mid-2018.
